×
News Home

How Will the Market React to ADMA Biologics Inc (ADMA) Stock Getting a Bullish Rating

Tuesday, May 17, 2022 04:34 PM | InvestorsObserver Analysts
How Will the Market React to ADMA Biologics Inc (ADMA) Stock Getting a Bullish Rating

The market has been high on ADMA Biologics Inc (ADMA) stock recently. ADMA gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bullish
ADMA Biologics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ADMA!

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With ADMA Stock Today?

ADMA Biologics Inc (ADMA) stock is trading at $2.02 as of 4:00 PM on Tuesday, May 17, an increase of $0.15, or 8.02% from the previous closing price of $1.87. The stock has traded between $1.88 and $2.03 so far today. Volume today is 3,180,391 compared to average volume of 2,857,012.

More About ADMA Biologics Inc

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. Click Here to get the full Stock Report for ADMA Biologics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App